August 20, 2018 07:23 AM EDT
Financing

Ab­b­Vie, Sanofi-backed Prin­cip­ia of­fers an $86M IPO af­ter burn­ing through $148M for pipeline work

John Carroll

Editor & Founder

It’s time for some new biotech IPOs to test the wa­ters on Nas­daq. With some sub­stan­tial back­ing from Sanofi and Ab­b­Vie, Prin­cip­ia Bio­Phar­ma out of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times